CIENCIASMEDICASNEWS

miércoles, 30 de septiembre de 2026

Hope for a precision medicine for ADNP syndrome 23 September 2026

Hope for a precision medicine for ADNP syndrome 23 September 2026 https://rarerevolutionmagazine.com/hope-for-a-precision-medicine-for-adnp-syndrome/ Genie and Rowland’s rare disease journey Typical of many busy families today, Genie Egerton-Warburton posts notes and calendars to a crowded household bulletin board. But some of the items on the Warburton board are unusual. There are sessions with occupational, educational, and physical therapists, visiting nurse and doctor appointments and a variety of reminders and charts. These entries are for Rowland, her 14-year-old son with a rare neurological disorder

The shift in antibody drug discovery From affinity to function, antibody discovery has shifted toward programmable biologics engineered to survive human physiology and execute complex therapeutic tasks at scale. Written byAndrea Corona

https://www.drugdiscoverynews.com/the-shift-in-antibody-drug-discovery-17021?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-83AGvtXKtrzP-Raxll3xEATtKmqRAOxHlAFxFypDaoeJJpL-eZLJWugQ9s9dWYtOBjvwbyx0BYyKQqs12z7E0Y3q-xSw&_hsmi=441645340&utm_content=441645340&utm_source=hs_email For three decades, the primary goal of antibody discovery was the refinement of binding affinity, maximizing the strength with which a monoclonal antibody (mAb) locked onto its target. But as we move through 2026, clinical milestones indicate a definitive pivot toward functional engineering. The modern antibody is no longer just a simple antagonist; it is a programmable scaffold designed to help overcome the physiological hurdles that once rendered most biologics ineffective.

Antibody discovery moves toward de novo design From computationally designed repertoires to AI-driven specificity prediction and multispecific therapeutics, antibody researchers are developing new ways to design molecules for the biology they need to influence. Written byBree Foster, PhD and Andrea Corona

Antibody discovery moves toward de novo design From computationally designed repertoires to AI-driven specificity prediction and multispecific therapeutics, antibody researchers are developing new ways to design molecules for the biology they need to influence. Written byBree Foster, PhD and Andrea Corona https://www.drugdiscoverynews.com/antibody-discovery-moves-toward-de-novo-design-17541?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9Qcy62gGqVoCB1arOfC3hVcscePxYUMwVMX6d0jxbcxdo_MSZ8WTV3u8VGdR8BHdt2r3ID73ba_PLH99Fkxw766IBMug&_hsmi=441645340&utm_content=441645340&utm_source=hs_email What if researchers could design antibodies with specific biological functions rather than simply search for molecules that bind a target? That question ran through The Antibody Series 2026 (TAS 2026), where speakers explored how computational design, AI, and increasingly complex antibody formats could expand what these therapies can do. But the conference also underscored a persistent challenge. Mark van Dijk, Head of Discovery at Fairjourney Bio, told DDN that antibody technology may no longer be the main limitation. Instead, “the biology is the limitation.”

A great antibody is not necessarily a great drug Antibody discovery is becoming less about finding the strongest binder and more about finding molecules that can survive the journey to the clinic. Written byBree Foster, PhD

A great antibody is not necessarily a great drug Antibody discovery is becoming less about finding the strongest binder and more about finding molecules that can survive the journey to the clinic. Written byBree Foster, PhD For years, antibody discovery has largely revolved around one question: Can the molecule bind its target and produce the desired biological effect? Increasingly, researchers are asking another question much earlier in the process: Can that antibody actually become a drug? Maria Gonzalez-Pajuelo, cofounder and Executive Vice President of Technology and Scientific Office at FairJourney Bio, told DDN that developability has become a much more important consideration during antibody discovery, rather than an issue left until later-stage development. https://www.drugdiscoverynews.com/a-great-antibody-is-not-necessarily-a-great-drug-17548

Navigating GLP-1 Switches: A Guide for Primary Care

https://www.medscape.com/viewarticle/navigating-glp-1-switches-guide-primary-care-2026a100107z?ecd=WNL_trdalrt_pos1_ous_260930_etid8746389&uac=148436CN&impID=8746389 As GLP-1 receptor agonists and dual incretin agents become more common in treating obesity and type 2 diabetes, primary care providers are handling more medication switches. The reason may be insurance coverage, ongoing gastrointestinal side effects, inadequate response, or the need for better blood sugar control or weight support. Whatever the driver, switching is not simply trading one prescription for another. It requires planning around half-lives, dose history, side effects, and the risk for blood sugar swings.

Clinical Crossroads of IDH-Mutant Glioma Care: Navigating Real-World Challenges and Complexities CME Philadelphia Marriott Downtown Friday, November 13, 2026 | 7:00 am - 8:15 am ET

https://na.eventscloud.com/website/99069/ The management of IDH-mutant glioma is evolving rapidly from traditional toxic therapies toward targeted molecular treatments and earlier intervention. Let our distinguished faculty guide you on effective integration of novel targeted therapies into your practice and how to navigate complex clinical scenarios through enhanced multidisciplinary coordination. SNO has reviewed and approved this symposium as appropriate for presentation as an Independent Supported Session. The session constitutes the content and views of the sponsor and is not part of the official 2026 SNO Annual Meeting program.